PMID- 17188427
OWN - NLM
STAT- MEDLINE
DCOM- 20070821
LR  - 20181113
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 253
IP  - 1
DP  - 2007 Aug 8
TI  - Tumor-suppressive activity of retinoic acid receptor-beta in cancer.
PG  - 14-24
AB  - Retinoids, a group of structural and functional analogs of vitamin A, are known 
      to regulate a large number of essential biological processes and to suppress 
      carcinogenesis. The effects of retinoids are mainly mediated by nuclear retinoid 
      receptors, which include retinoic acid receptors (RARs) and retinoid X receptors 
      (RXRs). Each receptor has three subtypes (alpha, beta, and gamma) and each 
      subtype has different isoforms. Retinoic acid receptor-beta (RAR-beta) has four 
      isoforms that have different affinities to retinoids and different biological 
      functions. Loss of expression of RAR-beta(2) during cancer development is 
      associated with tumorigenesis and retinoid resistance; induction of its 
      expression, on the other hand, can suppress carcinogenesis. Expression of another 
      isoform, RAR-beta(4), is increased in various types of cancer. RAR-beta(4) 
      transgenic mice develop hyperplasia and neoplasia in various tissues, and 
      induction of RAR-beta(4) expression increases the growth of tumor cells that do 
      not express RAR-beta(2). Future studies will focus on molecular pathways 
      involving RAR-beta(2) and the role of RAR-beta(4) in cancer development.
FAU - Xu, Xiao-Chun
AU  - Xu XC
AD  - Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M. 
      D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. 
      xxumdanderson.org
LA  - eng
GR  - R21 CA10226/CA/NCI NIH HHS/United States
GR  - R29 CA74835/CA/NCI NIH HHS/United States
GR  - R29 CA074835-02/CA/NCI NIH HHS/United States
GR  - R01 CA117895/CA/NCI NIH HHS/United States
GR  - R21 CA102265-02/CA/NCI NIH HHS/United States
GR  - R29 CA074835/CA/NCI NIH HHS/United States
GR  - R01 CA117895-01A2/CA/NCI NIH HHS/United States
GR  - R21 CA102265/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20061222
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Biomarkers)
RN  - 0 (Protein Isoforms)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (retinoic acid receptor beta)
SB  - IM
MH  - Base Sequence
MH  - Biomarkers/metabolism
MH  - Forecasting
MH  - Humans
MH  - Molecular Sequence Data
MH  - Neoplasms/*metabolism/prevention & control
MH  - Protein Isoforms/metabolism
MH  - Receptors, Retinoic Acid/genetics/*physiology
PMC - PMC2562790
MID - NIHMS26194
EDAT- 2006/12/26 09:00
MHDA- 2007/08/22 09:00
PMCR- 2008/10/07
CRDT- 2006/12/26 09:00
PHST- 2006/10/02 00:00 [received]
PHST- 2006/11/20 00:00 [revised]
PHST- 2006/11/22 00:00 [accepted]
PHST- 2006/12/26 09:00 [pubmed]
PHST- 2007/08/22 09:00 [medline]
PHST- 2006/12/26 09:00 [entrez]
PHST- 2008/10/07 00:00 [pmc-release]
AID - S0304-3835(06)00654-9 [pii]
AID - 10.1016/j.canlet.2006.11.019 [doi]
PST - ppublish
SO  - Cancer Lett. 2007 Aug 8;253(1):14-24. doi: 10.1016/j.canlet.2006.11.019. Epub 
      2006 Dec 22.